Within tauopathies, flortaucipir was found to have the highest binding to 3R/4R Alzheimer’s disease-like tau pathology, followed by 3R-dominant tauopathies (e.g. Pick’s disease) and 4R-dominant tauopathies (e.g. PSP, CBD, some FTLD-MAPT) and other mixed 3R/4R tauopathies (e.g. CTE).399-405 Several studies have demonstrated no or very minimal flortaucipir binding with TDP-43 pathology400,401,406 as well as with α-synuclein pathology.400,401,406. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.